News
The latest readout from INAVO120 marks the first time a PI3K-inhibiting targeted treatment has shown an overall survival advantage.
9d
Zacks.com on MSNLilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...
Hosted on MSN8mon
Relay up 5% as Street applauds breast cancer candidate dataThe company calls the candidate the "first known investigational allosteric, pan-mutant and isoform-selective inhibitor of PI3Kα." There was also a 33% objective response rate across all patients ...
We came across a bullish thesis on Relay Therapeutics, Inc. (RLAY) on Substack by Steve Wagner. In this article, we will summarize the bulls’ thesis on RLAY. Relay Therapeutics, Inc. (RLAY)’s share ...
ETX-636 preclinical data to be presented at the AACR annual meeting, showcasing superior potency and selectivity for all mutant forms of PI3Kα while sparing wildtype PI3Kα Mutant PI3Kα is a key ...
Ensem Therapeutics Inc. has gained IND clearance from the FDA for ETX-636, a novel allosteric pan-mutant-selective PI3Kα inhibitor and degrader. A first-in-human trial will begin this quarter. The ...
"We are thrilled to present the first clinical data for our lead program, OKI-219, which is the only highly selective PI3Kα H1047R inhibitor molecule in the clinic,” said Nicholas Saccomano, Ph.D., ...
The highlights included a potent KRAS inhibitor with impressive tumor growth inhibition in mouse models, a novel PI3Kα inhibitor demonstrating efficacy against key mutations, and a selective ...
BOULDER, Colo., May 06, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines in oncology, today ...
We also have leveraged our boron chemistry capabilities to identify multiple oncology candidates including potentially best-in-class inhibitors for ENPP1 and PI3Kα with our lead compound(s ...
We designed OKI-219 and our ongoing PIKture-01 trial to set a high bar for achieving considerable selectivity in targeting oncogenic PI3Kα H1047R. Late last year, we announced preliminary data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results